Notice of Correction to RFA-CA-19-033 "Improving Outcomes for Pediatric, Adolescent and Young Adult Cancer Survivors (U01 Clinical Trial Required)"

Notice Number: NOT-CA-19-058

Key Dates
Release Date: May 29, 2019

Related Announcements

RFA-CA-19-033

Issued by
National Cancer Institute (NCI)

Purpose

The purpose of this Notice is to inform potential applicants about a clarification regarding non-responsive applications for RFA-CA-19-033 "Improving Outcomes for Pediatric, Adolescent and Young Adult Cancer Survivors (U01 Clinical Trial Required)". The correction applies to Section I., Subheading, "Non-responsive Applications":

 

Part 2. Full Text of Announcement

Section I. Funding Opportunity Description

Purpose

Currently reads:

  • Applications proposing drug development studies. 

Modified to read:

  • Applications that propose development or testing of cancer-directed therapies.

This change applies to all applications to be submitted for the second (and final) receipt date of RFA-CA-19-033, i.e., January 3, 2020.

All other aspects of RFA-CA-19-033 remain unchanged.

Inquiries

For inquiries, contact:

Sandra Mitchell, Ph.D., CRNP
National Cancer Institute (NCI)
Telephone: 240-276-6929
Email: [email protected]

Or

Danielle Daee, Ph.D.
National Cancer Institute (NCI)
Telephone: 240-276-5744
Email: [email protected]